Quadrivalent vaccine evaluation study (QUEST)
Principal Investigators: Gina Ogilvie, Simon Dobson
Primary Contact: QUESTION Coordinating Centre, 604.875.2636 (Toll Free: 1-866-502-2424), firstname.lastname@example.org
About the Study: QUEST (Quadrivalent HPV Vaccine Evaluation Study) is a Canada-wide study designed to evaluate whether 2 doses of the HPV vaccine are just as effective as 3 doses at preventing Human Papillomavirus (HPV) infection and cervical cancer. The QUEST study will seek to recruit 8,666 females from across between the ages of 14 to 18. Study sites are in British Columbia, Alberta, Quebec, Nova Scotia, and PEI.
Why is the study important? A 2 dose schedule instead of 3 doses of the HPV vaccine means girls would have to endure fewer shots and the program could be extended to more people including boys. Fewer doses means that middle and lower income countries are more likely to be able to afford the HPV vaccine program.
Who can participate? Females 14-18 years old who received either 2 or 3 doses of the HPV vaccine on the provincial schedule who are located in BC, Alberta, Quebec, PIE or Nova Scotia.
What does participation involve? Participating is quick and simple and can be done from anywhere. Participants are enrolled in the study for 5 years and involves completing an online survey once a year and providing self collected swabs twice a year
Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Krajden M, van Niekerk DJ, Coldman AJ. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. Int J Cancer. 2015;137(8):1931-7.
Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W, McNeil S, Money D, Dionne M, Palefsky J, Karunakaran K, Kollmann T, Ogilvie G, Petric M, Dobson S. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine. 2014;32(5):624-30.
Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793-802.
Co-Investigators: Mel Krajden, Joel Singer, Marie Helene Mayrand, Shelly McNeil, Chantal Sauvageau, Vladmir Gilca, James Kellner, Deborah Money
Funded by: MSFHR, CIHR
Partners: UBC, CFRI, Dalhousie University, University of Calgary, Centre Hospitalier Universitaire de Quebec